AU2023269154B2 - Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist - Google Patents

Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist

Info

Publication number
AU2023269154B2
AU2023269154B2 AU2023269154A AU2023269154A AU2023269154B2 AU 2023269154 B2 AU2023269154 B2 AU 2023269154B2 AU 2023269154 A AU2023269154 A AU 2023269154A AU 2023269154 A AU2023269154 A AU 2023269154A AU 2023269154 B2 AU2023269154 B2 AU 2023269154B2
Authority
AU
Australia
Prior art keywords
compound
acceptable salt
pharmaceutically acceptable
atezolizumab
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2023269154A
Other languages
English (en)
Other versions
AU2023269154A1 (en
Inventor
Joanne Irene ADAMKEWICZ
Jennifer ENG-WONG
Pablo Saenz-Lopez LARROCHA
Jeffrey Lau
Danilo Maddalo
Mark Andrew MERCHANT
Gaurav PATHRIA
Nicole SODIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2023269154A1 publication Critical patent/AU2023269154A1/en
Application granted granted Critical
Publication of AU2023269154B2 publication Critical patent/AU2023269154B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2023269154A 2022-05-12 2023-05-12 Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist Active AU2023269154B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341361P 2022-05-12 2022-05-12
US63/341,361 2022-05-12
PCT/US2023/066920 WO2023220703A1 (en) 2022-05-12 2023-05-12 Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist

Publications (2)

Publication Number Publication Date
AU2023269154A1 AU2023269154A1 (en) 2024-10-10
AU2023269154B2 true AU2023269154B2 (en) 2026-05-14

Family

ID=86710772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023269154A Active AU2023269154B2 (en) 2022-05-12 2023-05-12 Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist

Country Status (10)

Country Link
US (1) US20250312339A1 (enExample)
EP (1) EP4522173A1 (enExample)
JP (1) JP2025516649A (enExample)
KR (1) KR20250012585A (enExample)
CN (1) CN119183377A (enExample)
AR (1) AR129314A1 (enExample)
AU (1) AU2023269154B2 (enExample)
CA (1) CA3248752A1 (enExample)
TW (1) TW202408523A (enExample)
WO (1) WO2023220703A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021061706A1 (en) * 2019-09-24 2021-04-01 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
DK3294770T4 (da) 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
EP3303632B2 (en) 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
US12281118B2 (en) * 2018-11-07 2025-04-22 Shanghai Ringene Biopharma Co., Ltd. Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021061706A1 (en) * 2019-09-24 2021-04-01 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKINLEYE AKINTUNDE ET AL: "Immune checkpoint inhibitors of PD-L1 as cancer therapeutics", JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, vol. 12, no. 1, 13 pages *

Also Published As

Publication number Publication date
KR20250012585A (ko) 2025-01-24
EP4522173A1 (en) 2025-03-19
JP2025516649A (ja) 2025-05-30
TW202408523A (zh) 2024-03-01
WO2023220703A1 (en) 2023-11-16
AU2023269154A1 (en) 2024-10-10
US20250312339A1 (en) 2025-10-09
CA3248752A1 (en) 2023-11-16
AR129314A1 (es) 2024-08-14
CN119183377A (zh) 2024-12-24

Similar Documents

Publication Publication Date Title
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
US12527784B2 (en) Combined pharmaceutical composition for treating small cell lung cancer
JP2021522298A (ja) 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
AU2019305857A1 (en) Drug combination of quinoline derivative and antibody
CN110494161A (zh) 用于治疗癌症的抗pd-l1抗体和dna-pk抑制剂的组合
AU2019231696A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
TWI806236B (zh) 用於治療肺癌之包含ｋｒａｓｇ１２ｃ抑制劑及ｐｄ-ｌ１結合拮抗劑的方法及組成物
AU2021397214B2 (en) Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors
JP2024529451A (ja) がんを治療するための方法及び組成物
CN111655725A (zh) 用于治疗癌症的组合产品
EP3930719B1 (en) Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
US20250312339A1 (en) Methods and compositions comprising a shp2 inhibitor and a pd-li binding antagonist
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
HK40113732A (en) Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
AU2021212193A1 (en) Anti-CD30 antibody-drug conjugates and their use for the treatment of non-Hodgkin lymphoma
HK40093627A (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
HK40109234A (en) Methods and compositions for treating cancer
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака